- Bupa Platinum consultant
-
Fee assured
-
Verified account
- Open Referral network
Offers
- Face-to-face consultations
- Video and telephone consultations
About me
I am a Consultant Clinical Oncologist specializing in the treatment of prostate cancer and oligometastatic cancers. I hold a substantive NHS consultant post at the Edinburgh Cancer Centre, where I serve as the Clinical Lead for Radiotherapy as well as the Uro-Oncology Clinical Trials Lead, bringing cutting-edge national and international clinical trials to patients across South East Scotland.
My clinical practice focuses on delivering precise, personalized cancer care using both advanced radiotherapy techniques and modern systemic anti-cancer therapies (chemotherapy, immunotherapy, and targeted treatments). I am passionate about optimizing treatment outcomes while minimizing toxicity through advanced technologies and biomarker-driven care.
Clinical Interests & Expertise
Advanced Radiotherapy: Image-Guided Intensity-Modulated Radiotherapy (IG-IMRT / VMAT) and Stereotactic Ablative Radiotherapy (SABR) for localized prostate cancer and oligometastatic disease.
Prostate Brachytherapy: Specialist expertise in Low-Dose-Rate (LDR) "seed" brachytherapy (monotherapy for favourable-risk prostate cancer) and High-Dose-Rate (HDR) brachytherapy boost. I lead the HDR prostate brachytherapy service at the Edinburgh Cancer Centre, having launched and delivered Scotland's first treatment via this service in April 2021.
Systemic Anti-Cancer Therapies (SACT): Extensive experience prescribing and managing modern systemic treatments, including chemotherapy (such as docetaxel and platinum-based agents), immunotherapies, and novel targeted anti-hormonal agents (abiraterone, enzalutamide, darolutamide, apalutamide, and Radium-223).
Training & Key Roles
Consultant Clinical Oncologist, Edinburgh Cancer Centre
Clinical Lead for Radiotherapy, Edinburgh Cancer Centre
Clinical Trials Lead for Uro-Oncological Cancers, South East Scotland Cancer Network (SCAN)
Clinical & Research Fellowship in Genitourinary Malignancies and Prostate Brachytherapy, Princess Margaret Cancer Centre, Toronto
Recipient of the CARO-ACURA Grant for focal dose-escalation research in prostate cancer
Areas of interest
Prostate cancer, Radiotherapy, Brachytherapy, SABR, Chemotherapy,Immunotherapy, novel anti-hormonal agents
Medical secretaries
- Lavanya A
- gu.medical@outlook.com
- Marie Quinn
- GU.medical@outlook.com
Information for healthcare professionals (Bupa patients only, last 12 months)
-
X0004
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (>50)
-
X6773
Preparation for simple radiotherapy with Intensity Modulated Radiotherapy (IMRT) - (1-5)
-
BT212
Insertion of low dose rate radioactive agent (brachytherapy) into prostate tumour - (1-5)
-
X0008
Clinical supervision of external beam radiotherapy, for 16 or up to and including 30 fractions - (1-5)
-
X6710
Preparation for rotational Intensity Modulated Radiotherapy (IMRT) (eg VMAT, RapidArc, Tomotherapy) - (1-5)